Rambam Health Care Campus Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01470352
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Endocrine Institute, Rambam Health Care Campus | The Rambam Academic Hospital

Active Ingredients

Drugs in Phase 2 Trials (1)

emapalumab-lzsg (gamifant) (1 trial)

Drugs in Other Trials (2)

duloxetine (Cymbalta) (1 trial)

olive (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3